Lacy MQ et al. Pomalidomide plus low dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: Comparison of two dosing strategies in dual-refractory disease. Proc ASH 2010;Abstract 863.

Leleu X et al. Phase 2 study of 2 modalities of pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. IFM 2009-02. Proc ASH 2010;Abstract 859.

Dr Fonseca is Consultant and Professor of Medicine at the Mayo Clinic Arizona and Deputy Director of the Mayo Clinic Cancer Center in Scottsdale, Arizona.